Results 1 to 10 of about 22,607 (134)
Microbiology Spectrum, 2021 Tigecycline is regarded as a last-resort treatment for multidrug-resistant Acinetobacter baumannii. However, tigecycline resistance in A. baumannii has increased worldwide. In this study, we investigated tigecycline heteroresistance in A.
Kwan Soo Ko
exaly +3 more sources
Frontiers in Cellular and Infection Microbiology, 2022 The increasing incidence of tigecycline resistance undoubtedly constitutes a serious threat to global public health. The combination therapies had become the indispensable strategy against this threat. Herein, 11 clinical tigecycline-resistant Klebsiella
Lang Sun, Xiukun Wang, Tongying Nie
exaly +3 more sources
Effect of sub-inhibitory tigecycline (½-MIC) on AcrAB-TolC and mar/ram/sox regulatory genes in Enterobacter cloacae complex isolates [PDF]
Frontiers in Cellular and Infection MicrobiologyThe global rise of antimicrobial resistance (AMR) in Enterobacterales, including the Enterobacter cloacae complex, is narrowing treatment options.
Lukasz Korczak +4 more
doaj +2 more sources
Tigecycline for severe Clostridium difficile infection
International Journal of Infectious Diseases, 2014 Limited data suggest that tigecycline may be of value in the treatment of Clostridiumdifficile infection. We reviewed our experience using tigecycline to treat severe c.
Nizam Uddin, Mark R Wallace
exaly +3 more sources
Environment International, 2019 This study aimed to investigate the impact of tigecycline, the third generation tetracycline, on the antibiotic resistance development in environmental microbiota.
Ruyin Liu, Min Yang, Yu Zhang
exaly +3 more sources
Journal of Antimicrobial Chemotherapy, 2005 New antimicrobial agents are urgently needed for clinical use due to the increasing prevalence and spread of multidrug-resistant bacteria that are commonly responsible for serious and life-threatening diseases. The need to develop new agents that effectively overcome existing mechanisms of resistance displayed by bacteria resistant to currently ...
James E, Frampton, Monique P, Curran
+7 more sources
Antibiotics, 2022 Acinetobacter baumannii is one of the main pathogens causing nosocomial and community-acquired infections. Tigecycline is an important antibiotic for the treatment of multidrug-resistant A.
Ping Wang +5 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Background: Tigecycline and cefoperazone/sulbactam can cause coagulation disorders; tigecycline may also lead to hypofibrinogenemia, raising safety concerns.
Lei Zhang +6 more
doaj +1 more source
Microbiology Spectrum, 2022 Acinetobacter baumannii is an important opportunistic pathogen of nosocomial infections. A. baumannii presently exhibits increasing antibiotic resistance, which poses great challenges to public health. The occurrence of tigecycline-resistant A. baumannii
Jiangang Zhang +8 more
doaj +1 more source
Journal of Postgraduate Medicine, 2009 Infection with resistant pathogens can adversely affect clinical, microbiological and economic outcomes. New agents for the treatment of many such serious infections are acutely needed in hospital practice. Tigecycline is a novel glycylcycline antimicrobial for intravenous use.
Bhattacharya, M., Parakh, A., Narang, M.
+5 more sources